Latest News - AbbVie
Top Corporates Hub
AbbVie
Is AbbVie (ABBV) Fully Valued After Its Tepkinly Approval?
08.07.2026 00:22
AbbVie (ABBV) is back in focus after the European Commission granted marketing authorization for Tepkinly plus lenalidomide and rituximab in relapsed or refractory follicular lymphoma, a chemotherapy free bispecific-based regimen for second line treatment. See our latest analysis for AbbVie. Against this backdrop of oncology approvals and index inclusions, AbbVie’s recent momentum is clear, with a 30 day share price return of 12.07% and a 90 day share price return of 20.35%, while 1 year...
Update: Tech Stock Decline, Oil Price Increase Dampen US Equity Futures Pre-Bell
07.07.2026 12:54
(Updates with stock and oil price moves, and additional details from sixth paragraph onward.) US
3 Market-Beating Stocks Worth Investigating
07.07.2026 12:01
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
3 Dividend Aristocrats to Buy in July
07.07.2026 12:00
Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine firing on all cylinders, and a home improvement giant priced for a ... 3 Dividend Aristocrats to Buy in July
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06.07.2026 17:45
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 trial, which evaluated fixed-duration TEPKINLY in combination with R2 compared to standard of care R2.
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
06.07.2026 14:50
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
Cannabis Theme Rally Powered by Profitability, Not Pure-Play Speculation
03.07.2026 12:35
Recent cannabis theme strength is driven by large, profitable firms like AbbVie, Altria, and Jazz Pharma, not pure-play operators. These cash-flow giants offer value, momentum, and defensive income.
AbbVie: Apogee Deal Just Widened An Already Dominant Moat
02.07.2026 00:47
AbbVieâs $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See more on ABBV here.
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
01.07.2026 11:00
Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours. Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announc
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
30.06.2026 08:27
This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaborationUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales Tokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reache
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
29.06.2026 07:10
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
29.06.2026 07:10
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
29.06.2026 07:00
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
28.06.2026 08:45
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
AbbVie (ABBV) Wins Health Canada Approval for Boey
28.06.2026 00:07
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?
26.06.2026 01:10
Earlier this week, AbbVie reported European Commission approvals extending Skyrizi to children with moderate to severe plaque psoriasis and making Maviret the only therapy cleared in the EU for both acute and chronic hepatitis C infection from age three. These label expansions broaden AbbVie’s reach in immunology and virology by opening earlier treatment windows and adding pediatric populations in high-need diseases. We’ll now explore how Skyrizi’s new pediatric indication and Maviret’s...
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
25.06.2026 03:35
AbbVie Inc. (NYSE:ABBV) is included among the Top 10 Blue Chip Stocks with Growing Dividends. On June 23, Canaccord raised its price recommendation on AbbVie Inc. (NYSE:ABBV) to $273 from $265. It reiterated a Buy rating on the shares. The firm updated its model following AbbVie’s announced acquisition of Apogee Therapeutics (APGE). Canaccord said the […]
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
23.06.2026 14:50
AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.
AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV)
23.06.2026 12:45
European Commission Expands Skyrizi Label to Younger PatientsAbbVie (NYSE:ABBV) has received approval from the European Commission to use Skyrizi (risankizumab) in children and adolescents aged six years and older with moderate-to-severe plaque psoriasis who are eligible for systemic treatment. The authorization broadens the medicine’s reach within Europe and provides a new treatment option for younger patients living with the chronic inflammatory skin condition.
Piper Sandler Reiterates Overweight on AbbVie, Maintains $298 Price Target
23.06.2026 12:19
Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $298 price target.